• Clinical Evidence

A Case Study: The Use of EndoTool in Obstetrics

Setting: 1,018-bed not-for-profit academic medical center and Level 1 trauma center.

Objective

This retrospective case study compares glycemic outcomes for labor and delivery patients before and after implementation of EndoTool (i.e., versus a paper protocol).

Setting

1,018-bed not-for-profit academic medical center and Level 1 trauma center.

Results

  • Incidence of hypoglycemia <70 mg/dL decreased 39.1% with EndoTool, from 4.6% to 2.8% of blood glucose readings.
  • Incidence of hypoglycemia <60 mg/dL decreased 42.9% with EndoTool, from 1.4% to 0.8% of blood glucose readings.
  • Average time to goal range of 70-100 mg/dL decreased 68.8% with EndoTool, from 12.5 to 3.9 hours.
  • Percentage of blood glucose measurements in the goal range increased 115.8% with EndoTool, from 19% to 41%.

Conclusions

Use of EndoTool for labor and delivery patients, including those with diabetes and DKA, provides markedly better glycemic outcomes than a paper protocol, as evidenced by lower incidence of hypoglycemia, significantly faster time to goal and a much higher percentage of blood glucose measurements in the goal range.
Objective

This retrospective case study compares glycemic outcomes for labor and delivery patients before and after implementation of EndoTool (i.e., versus a paper protocol).

Setting

1,018-bed not-for-profit academic medical center and Level 1 trauma center.

Results
  • Incidence of hypoglycemia <70 mg/dL decreased 39.1% with EndoTool, from 4.6% to 2.8% of blood glucose readings.
  • Incidence of hypoglycemia <60 mg/dL decreased 42.9% with EndoTool, from 1.4% to 0.8% of blood glucose readings.
  • Average time to goal range of 70-100 mg/dL decreased 68.8% with EndoTool, from 12.5 to 3.9 hours.
  • Percentage of blood glucose measurements in the goal range increased 115.8% with EndoTool, from 19% to 41%.
Conclusions

Use of EndoTool for labor and delivery patients, including those with diabetes and DKA, provides markedly better glycemic outcomes than a paper protocol, as evidenced by lower incidence of hypoglycemia, significantly faster time to goal and a much higher percentage of blood glucose measurements in the goal range.

References

Authors

Maresa Glass, PharmD, BCPS, BCCCP.

Source

Presented at EndoTool® User Group Meeting.

Year

2018

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This retrospective case study compares glycemic outcomes for labor and delivery patients before and after implementation of EndoTool (i.e., versus a paper protocol).

Setting

1,018-bed not-for-profit academic medical center and Level 1 trauma center.

Results
  • Incidence of hypoglycemia <70 mg/dL decreased 39.1% with EndoTool, from 4.6% to 2.8% of blood glucose readings.
  • Incidence of hypoglycemia <60 mg/dL decreased 42.9% with EndoTool, from 1.4% to 0.8% of blood glucose readings.
  • Average time to goal range of 70-100 mg/dL decreased 68.8% with EndoTool, from 12.5 to 3.9 hours.
  • Percentage of blood glucose measurements in the goal range increased 115.8% with EndoTool, from 19% to 41%.
Conclusions

Use of EndoTool for labor and delivery patients, including those with diabetes and DKA, provides markedly better glycemic outcomes than a paper protocol, as evidenced by lower incidence of hypoglycemia, significantly faster time to goal and a much higher percentage of blood glucose measurements in the goal range.

References

Authors

Maresa Glass, PharmD, BCPS, BCCCP.

Source

Presented at EndoTool® User Group Meeting.

Year

2018

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

To evaluate the impact of EndoTool IV insulin dosing software on reducing severe hypoglycemia (SH) (blood glucose < 40 mg/dL) across 19-hospitals at a prominent health system, including outcomes in patients with renal insufficiency.
Image
  • Clinical Evidence

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

To evaluate the safety and efficacy of the EndoTool SubQ (ETSQ) insulin dosing application for subcutaneous (SQ) insulin administration in hospitalized patients, and to compare clinical outcomes against those treated using a standard insulin order set. The analysis also examined performance in high-risk patients with advanced renal impairment.
Image
  • Clinical Evidence

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Temple Health, a 3-hospital academic system was experiencing high rates of hypoglycemia due to reliance on sliding scale insulin (SSI). To improve safety and align with ADA guidelines, the hospital implemented EndoTool SubQ, a patient-specific insulin dosing software the supports four dosing protocols, including basal-bolus-correction (BBC).
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
By submitting this form, you consent to the processing of your personal information, including sensitive personal information you provide, in accordance with the Monarch Medical Technologies Privacy Notice.